Synthesis of New Imidazolo‐Benzenesulfonamide Linked 1,2,3‐Triazoles as Potent Antibacterial and Antibiofilm Agents

Abstract In search of better antibacterial and antibiofilm agents, this report presents a series of novel 1,2,3‐triazole‐imidazole‐benzenesulfonamide derivatives that were synthesized and evaluated for their antibacterial and antibiofilm activity in vitro. Antibacterial activity against three Gram‐positive bacterial strains, B. subtilis , S. aureus , and S. epidermidis , was evaluated. Among all the tested compounds, 4‐methyl‐ N ‐(1‐methyl‐1 H ‐imidazol‐2‐yl)‐ N ‐((1‐(4‐(trifluoromethyl)phenyl)‐1 H ‐1,2,3‐triazol‐4‐yl)methyl)benzenesulfonamide and N ‐((1‐(3,5‐difluorophenyl)‐1 H ‐1,2,3‐triazol‐4‐yl)methyl)‐4‐methyl‐ N ‐(1‐methyl‐1 H ‐imidazol‐2‐yl)benzenesulfonamide exhibited potent antibacterial activity against S. aureus and B. subtilis bacterial strains. Biofilm profiles for the potent compounds and it was observed from the results that the above two active compounds displayed promising biofilm inhibition against B. subtilis and S. aureus , with MIC values ranging between 2.19 ± 0.37 and 3.38 ± 0.35 µg/mL. Furthermore, potent compounds screened for their in silico molecular docking studies against penicillin‐binding protein and compound N ‐((1‐(3,5‐dichlorophenyl)‐1 H ‐1,2,3‐triazol‐4‐yl)methyl)‐4‐methyl‐ N ‐(1‐methyl‐1 H ‐imidazol‐2‐yl)benzenesulfonamide show highest binding energy as compared to the standard and remaining compounds.